Product Information
ZOVIRAX 5% OINTMENT is a brand product labeled by Bausch Health US LLC, priced at $4.7770 per GM under NDC 00187099395. Its NADAC has been published 276 times since Nov 28, 2013.
FDA first approved this application on Mar 29, 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the acyclovir market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
50 mg/g
Manufacturer
Bausch Health US LLCNDC
00187099395
Classification
Brand
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/17/2025
Active Ingredients
ACYCLOVIRApproval Type
New Drug (NDA)
FDA Application
NDA018604FDA Approved
3/29/1982
TE Code
AB
On Market Since
3/29/1982
Pharmacological Classes
Price Statistics
The NADAC for ZOVIRAX 5% OINTMENT has been published 276 times since Nov 28, 2013, and over the history we have for it it has declined 79.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.7770 per GM |
|---|---|
| All-time high | $46.8015 (Feb 12, 2020) |
| All-time low | $4.7770 (Sep 17, 2025) |
| Median price | $34.9117 |
| Average price | $28.5594 |
| Largest weekly change | -89.7% (Apr 17, 2024) |
| Weeks tracked | 276 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-89.8%
5Y
-89.8%
All
-79.9%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 93% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch Health US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
acyclovir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZOVIRAX 5% OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for ZOVIRAX 5% OINTMENT, manufactured by Bausch Health US LLC, is $4.7770 per GM (NDC 00187099395), effective Oct 1, 2025.
How has the price of ZOVIRAX 5% OINTMENT changed over time?
Over the history we have for it, the NADAC for ZOVIRAX 5% OINTMENT has declined 79.9%. It has been tracked across 276 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ZOVIRAX 5% OINTMENT?
Since Nov 28, 2013, the NADAC for ZOVIRAX 5% OINTMENT has ranged from a low of $4.7770 (Sep 17, 2025) to a high of $46.8015 (Feb 12, 2020), with a median of $34.9117 per GM.
Are there cheaper alternatives to ZOVIRAX 5% OINTMENT?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACYCLOVIR 5% OINTMENT, is $0.3149 per GM — about 93% below ZOVIRAX 5% OINTMENT.
Who manufactures ZOVIRAX 5% OINTMENT?
ZOVIRAX 5% OINTMENT (NDC 00187099395) is labeled by Bausch Health US LLC, and CMS classifies it as a brand product.